Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04268888
Title Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Clatterbridge Cancer Centre NHS Foundation Trust
Indications

hepatocellular carcinoma

Therapies

Nivolumab

Age Groups: child | senior | adult
Covered Countries


No variant requirements are available.